D. Boral Capital Reiterates Buy Rating for Anavex Life Sciences (NASDAQ:AVXL)

Anavex Life Sciences (NASDAQ:AVXL)‘s stock had its “buy” rating reaffirmed by equities researchers at D. Boral Capital in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $46.00 price target on the biotechnology company’s stock. D. Boral Capital’s price target would suggest a potential upside of 368.43% from the stock’s current price.

Separately, HC Wainwright reissued a “buy” rating and issued a $42.00 price objective on shares of Anavex Life Sciences in a research report on Tuesday, January 21st.

Anavex Life Sciences Stock Performance

Shares of Anavex Life Sciences stock opened at $9.82 on Tuesday. The business’s 50 day simple moving average is $9.92 and its 200 day simple moving average is $7.46. The firm has a market cap of $832.93 million, a PE ratio of -18.88 and a beta of 0.70. Anavex Life Sciences has a 52-week low of $3.25 and a 52-week high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL) last posted its quarterly earnings data on Monday, December 23rd. The biotechnology company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. As a group, equities research analysts predict that Anavex Life Sciences will post -0.73 EPS for the current year.

Hedge Funds Weigh In On Anavex Life Sciences

Several large investors have recently modified their holdings of AVXL. JPMorgan Chase & Co. grew its stake in Anavex Life Sciences by 2.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 42,565 shares of the biotechnology company’s stock valued at $242,000 after buying an additional 1,191 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Anavex Life Sciences by 10.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 17,980 shares of the biotechnology company’s stock worth $193,000 after acquiring an additional 1,671 shares during the period. Foster Victor Wealth Advisors LLC increased its stake in shares of Anavex Life Sciences by 5.6% during the fourth quarter. Foster Victor Wealth Advisors LLC now owns 37,663 shares of the biotechnology company’s stock worth $405,000 after purchasing an additional 2,000 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in Anavex Life Sciences by 8.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 30,510 shares of the biotechnology company’s stock worth $129,000 after purchasing an additional 2,401 shares during the last quarter. Finally, Carnegie Investment Counsel boosted its stake in Anavex Life Sciences by 4.7% in the 4th quarter. Carnegie Investment Counsel now owns 76,778 shares of the biotechnology company’s stock valued at $825,000 after purchasing an additional 3,445 shares during the period. 31.55% of the stock is owned by institutional investors.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.